Aardvark Therapeutics (AARD) vs Citius Oncology (CTOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Citius Oncology (CTOR) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 54.8% versus a loss of 70.5%. Aardvark Therapeutics is the larger company by market cap ($82.7 million vs $81.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | CTOR |
|---|---|---|
| Share price | $3.78 | $0.7679 |
| Market cap | $82.72M | $81.21M |
| 1-day change | -2.07% | +2.94% |
| YTD return | -71.20% | -23.21% |
| 1-year return | -70.49% | -54.83% |
| EPS (TTM) | $-3.21 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-57.59M | $-24.76M |
| 52-week high | $16.60 | $1.95 |
| 52-week low | $3.35 | $0.491 |
| Distance from 52-week high | -77.23% | -60.62% |
| Analyst consensus | buy | none |
| Avg. price target upside | +193.92% | +420.90% |
| Average volume | 131.56K | 102.94K |
| Shares outstanding | 21.88M | 105.76M |
| Employees | 28 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTOR has outperformed AARD by 15.7 percentage points over the past year.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Citius Oncology
CTOR stock →Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations
AARD vs CTOR FAQ
Which is bigger, Aardvark Therapeutics or Citius Oncology?
Aardvark Therapeutics (AARD) is larger, with a market capitalization of $82.72M compared with $81.21M for Citius Oncology (CTOR).
Which stock has performed better over the past year, AARD or CTOR?
CTOR returned -54.83% over the past 12 months, compared with -70.49% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and Citius Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.